232 related articles for article (PubMed ID: 38050338)
1. Plant-derived Durvalumab variants show efficient PD-1/PD-L1 blockade and therapeutically favourable FcR binding.
Izadi S; Gumpelmair S; Coelho P; Duarte HO; Gomes J; Leitner J; Kunnummel V; Mach L; Reis CA; Steinberger P; Castilho A
Plant Biotechnol J; 2024 May; 22(5):1224-1237. PubMed ID: 38050338
[TBL] [Abstract][Full Text] [Related]
2. Fc glycoengineering of a PD-L1 antibody harnesses Fcγ receptors for increased antitumor efficacy.
Cohen Saban N; Yalin A; Landsberger T; Salomon R; Alva A; Feferman T; Amit I; Dahan R
Sci Immunol; 2023 Mar; 8(81):eadd8005. PubMed ID: 36867679
[TBL] [Abstract][Full Text] [Related]
3. Efficient PD-L1 imaging of murine glioblastoma with FUS-aided immunoPET by leveraging FcRn-antibody interaction.
Chevaleyre C; Novell A; Tournier N; Dauba A; Dubois S; Kereselidze D; Selingue E; Jego B; Maillère B; Larrat B; Nozach H; Truillet C
Theranostics; 2023; 13(15):5584-5596. PubMed ID: 37908736
[No Abstract] [Full Text] [Related]
4. Blockade of LAG-3 in PD-L1-Deficient Mice Enhances Clearance of Blood Stage Malaria Independent of Humoral Responses.
Furtado R; Chorro L; Zimmerman N; Guillen E; Spaulding E; Chin SS; Daily JP; Lauvau G
Front Immunol; 2020; 11():576743. PubMed ID: 33519801
[TBL] [Abstract][Full Text] [Related]
5. Avelumab internalization by human circulating immune cells is mediated by both Fc gamma receptor and PD-L1 binding.
Jin H; D'Urso V; Neuteboom B; McKenna SD; Schweickhardt R; Gross AW; Fomekong Nanfack Y; Paoletti A; Carter C; Toleikis L; Fluck M; Scheuenpflug J; Cai T
Oncoimmunology; 2021; 10(1):1958590. PubMed ID: 34484871
[TBL] [Abstract][Full Text] [Related]
6. Multi-Angle Effector Function Analysis of Human Monoclonal IgG Glycovariants.
Dashivets T; Thomann M; Rueger P; Knaupp A; Buchner J; Schlothauer T
PLoS One; 2015; 10(12):e0143520. PubMed ID: 26657484
[TBL] [Abstract][Full Text] [Related]
7. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.
Vafa O; Gilliland GL; Brezski RJ; Strake B; Wilkinson T; Lacy ER; Scallon B; Teplyakov A; Malia TJ; Strohl WR
Methods; 2014 Jan; 65(1):114-26. PubMed ID: 23872058
[TBL] [Abstract][Full Text] [Related]
8. Blocking PD-1/PD-L1 by an ADCC enhanced anti-B7-H3/PD-1 fusion protein engages immune activation and cytotoxicity.
Xu Y; Xiao Y; Luo C; Liu Q; Wei A; Yang Y; Zhao L; Wang Y
Int Immunopharmacol; 2020 Jul; 84():106584. PubMed ID: 32422527
[TBL] [Abstract][Full Text] [Related]
9. Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids.
Hamdan F; Ylösmäki E; Chiaro J; Giannoula Y; Long M; Fusciello M; Feola S; Martins B; Feodoroff M; Antignani G; Russo S; Kari O; Lee M; Järvinen P; Nisen H; Kreutzman A; Leusen J; Mustjoki S; McWilliams TG; Grönholm M; Cerullo V
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34362830
[TBL] [Abstract][Full Text] [Related]
10. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
11. LIGHT (TNFSF14) Costimulation Enhances Myeloid Cell Activation and Antitumor Immunity in the Setting of PD-1/PD-L1 and TIGIT Checkpoint Blockade.
Yoo KJ; Johannes K; González LE; Patel A; Shuptrine CW; Opheim Z; Lenz K; Campbell K; Nguyen TA; Miriyala J; Smith C; McGuire A; Tsai YH; Rangwala F; de Silva S; Schreiber TH; Fromm G
J Immunol; 2022 Aug; 209(3):510-525. PubMed ID: 35817517
[TBL] [Abstract][Full Text] [Related]
12. Development and functional analysis of an anticancer T-cell medicine with immune checkpoint inhibitory ability.
Fujiwara K; Shigematsu K; Tachibana M; Okada N
IUBMB Life; 2020 Aug; 72(8):1649-1658. PubMed ID: 32255257
[TBL] [Abstract][Full Text] [Related]
13. Human adipose-derived mesenchymal stem cells prevent type 1 diabetes induced by immune checkpoint blockade.
Kawada-Horitani E; Kita S; Okita T; Nakamura Y; Nishida H; Honma Y; Fukuda S; Tsugawa-Shimizu Y; Kozawa J; Sakaue T; Kawachi Y; Fujishima Y; Nishizawa H; Azuma M; Maeda N; Shimomura I
Diabetologia; 2022 Jul; 65(7):1185-1197. PubMed ID: 35511238
[TBL] [Abstract][Full Text] [Related]
14. The binding of an anti-PD-1 antibody to FcγRΙ has a profound impact on its biological functions.
Zhang T; Song X; Xu L; Ma J; Zhang Y; Gong W; Zhang Y; Zhou X; Wang Z; Wang Y; Shi Y; Bai H; Liu N; Yang X; Cui X; Cao Y; Liu Q; Song J; Li Y; Tang Z; Guo M; Wang L; Li K
Cancer Immunol Immunother; 2018 Jul; 67(7):1079-1090. PubMed ID: 29687231
[TBL] [Abstract][Full Text] [Related]
15. Sanguisorbae Radix Suppresses Colorectal Tumor Growth Through PD-1/PD-L1 Blockade and Synergistic Effect With Pembrolizumab in a Humanized PD-L1-Expressing Colorectal Cancer Mouse Model.
Lee EJ; Kim JH; Kim TI; Kim YJ; Pak ME; Jeon CH; Park YJ; Li W; Kim YS; Choi JG; Chung HS
Front Immunol; 2021; 12():737076. PubMed ID: 34659228
[TBL] [Abstract][Full Text] [Related]
16. Fc-null anti-PD-1 monoclonal antibodies deliver optimal checkpoint blockade in diverse immune environments.
Moreno-Vicente J; Willoughby JE; Taylor MC; Booth SG; English VL; Williams EL; Penfold CA; Mockridge CI; Inzhelevskaya T; Kim J; Chan HTC; Cragg MS; Gray JC; Beers SA
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35017153
[TBL] [Abstract][Full Text] [Related]
17. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
Garassino MC; Cho BC; Kim JH; Mazières J; Vansteenkiste J; Lena H; Corral Jaime J; Gray JE; Powderly J; Chouaid C; Bidoli P; Wheatley-Price P; Park K; Soo RA; Huang Y; Wadsworth C; Dennis PA; Rizvi NA;
Lancet Oncol; 2018 Apr; 19(4):521-536. PubMed ID: 29545095
[TBL] [Abstract][Full Text] [Related]
18. Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma.
Faiena I; Cummings AL; Crosetti AM; Pantuck AJ; Chamie K; Drakaki A
Drug Des Devel Ther; 2018; 12():209-215. PubMed ID: 29416316
[TBL] [Abstract][Full Text] [Related]
19. Genetic engineering cellular vesicles expressing CD64 as checkpoint antibody carrier for cancer immunotherapy.
Li L; Miao Q; Meng F; Li B; Xue T; Fang T; Zhang Z; Zhang J; Ye X; Kang Y; Zhang X; Chen Q; Liang X; Chen H; Zhang X
Theranostics; 2021; 11(12):6033-6043. PubMed ID: 33897897
[TBL] [Abstract][Full Text] [Related]
20. Cross-species analysis of Fc engineered anti-Lewis-Y human IgG1 variants in human neonatal receptor transgenic mice reveal importance of S254 and Y436 in binding human neonatal Fc receptor.
Burvenich IJ; Farrugia W; Lee FT; Catimel B; Liu Z; Makris D; Cao D; O'Keefe GJ; Brechbiel MW; King D; Spirkoska V; Allan LC; Ramsland PA; Scott AM
MAbs; 2016; 8(4):775-86. PubMed ID: 27030023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
